Latest news with #newborns
Khaleej Times
14-07-2025
- Health
- Khaleej Times
Abu Dhabi: New mothers to get timely support with home visits, online consultation
The Department of Health – Abu Dhabi (DoH) has launched the Integrated Postnatal Care Programme as part of its broader Women's and Children's Health Strategy, in a bid to improve outcomes for mothers and newborns during the crucial postpartum period. The new initiative offers a comprehensive and accessible care model that combines home visits, telemedicine consultations, and outpatient services. It aims to ensure that new mothers receive continuous, personalised support from the moment of discharge through the weeks that follow — helping identify potential concerns early and ensuring timely intervention. As part of the programme, a telemedicine consultation will be offered shortly after a mother and baby leave the hospital. This early virtual check-in is designed to monitor their health and wellbeing, provide expert guidance, and address any immediate concerns — offering peace of mind during the early days at home. In addition, mothers will have the option to visit their nearest hospital or primary care clinic at two key stages: between 7 and 14 days postpartum, and again at six weeks. For mothers who experienced complications during pregnancy or childbirth, or are caring for infants with special health needs, the programme also includes two home visits by a nurse or midwife. The first occurs shortly after discharge, and the second between 7 and 14 days later, offering hands-on support in a familiar environment. 'The postpartum period is one of the most physically and emotionally challenging times in a woman's life – and yet, one of the most overlooked. With the launch of this programme, we prioritise mothers and newborns by providing a robust support system that extends beyond the hospital walls," said Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH). "By integrating telemedicine, in-person follow-ups, and home-based care, we deliver proactive, personalised services that empower mothers and give every child a healthier start. This is more than just a healthcare programme – it's a commitment to ensuring that every mother and child receives the highest quality of care they deserve," she added.
Yahoo
13-07-2025
- General
- Yahoo
Aultman, Mercy births for June 22-28
AULTMAN HOSPITAL June 22, 2025 Christi and Brandon Romeo of Brewster, girl Lauren Jones and Matthew Cannon of Atwater, boy Mollie Miller and Shawn Douglas of Canton, boy June 23, 2025 Alivia and Jordan Tozzi of Massillon, boy Lizabeth and Justin Burns of Massillon, girl June 24, 2025 Taylor and Tyler McIlvain of Canton, boy Alexis and Alexander Delancey of Lowell, girl Jessica and Jonathan Cosgray of Sebring, girl Lilia and Joshua Miller of Navarre, boy June 25, 2025 Christina Bechter of Canton, boy Erin Montgomery and Louis Horner of Massillon, boy Jessica Jackson of Canton, girl Rebecca and Steven Hammond of Massillon, boy Taylor Metzgar and Charles Lemley of Alliance, boy June 26, 2025 Destiny and Noah McKinney of Dellroy, boy Kimberly and Brent Vigil of Massillon, girl Kayla Wiseman and Brandon Reed of Alliance, girl Marisa Sheets and Alex Mitchell of Canton, girl June 27, 2025 Jessica White and David Minor of Malvern, boy Hope and Jason Foster of Carrollton, girl Ella Mae Senior and Ja'veon Ware of Canton, girl June 28, 2025 Morgan Terry-Stutler and Cody Stutler of Louisville, girl CLEVELAND CLINIC MERCY HOSPITAL June 23, 2025 Jalisa Johnson and Marquez Merriweather of Canton, boy June 25, 2025 Bonnie and Nathaniel Faile of Massillon, girl June 27, 2025 Hannah and Maverick Kostich of Massillon, boy This article originally appeared on The Repository: Aultman, Mercy births for June 22-28
CNN
09-07-2025
- Health
- CNN
First malaria drug for newborns and young infants expected to be approved in Africa within weeks
The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, drugmaker Novartis said Tuesday. The drug, known as Coartem Baby or Riamet Baby in some countries, has been approved by Swiss authorities for use in babies weighing between 2 kilograms (4 pounds, 6 ounces) and 5 kilograms (11 pounds) and is formulated to be easy for them to take, Novartis said. Coartem Baby already has approval in the West African nation of Ghana and Novartis said it now expects eight African countries to grant their own approvals within 90 days. The countries – Burkina Faso, Cote d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda – also participated in the assessment of the drug. Vas Narasimhan, chief executive of Novartis, said in a news release that this first clinically proven malaria treatment for newborns and young babies ensures 'even the smallest and most vulnerable can finally receive the care they deserve.' Until now, the smallest babies have been treated for malaria, a potentially deadly disease spread by mosquitoes, with medications designed for older children. Novartis, the Swiss pharmaceutical corporation behind the newly approved drug, says this can expose newborns to the risk of overdose and toxicity. 'Most clinical trials have historically excluded babies under six months old,' Novartis spokesman Ruairidh Villar told CNN. There were 263 million cases of malaria and 597,000 deaths in 2023 – nearly all of them in Africa, according to World Health Organization data. Children under the age of 5 accounted for about three in four malaria deaths in the region. The medicine was developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV), a Switzerland-based not-for-profit organization. Novartis told CNN that it plans to 'roll out the medicine in the coming weeks on a largely not-for-profit basis.' 'Malaria is one of the world's deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated,' said Martin Fitchet, chief executive of MMV. 'The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox.'
CNN
09-07-2025
- Health
- CNN
First malaria drug for newborns and young infants expected to be approved in Africa within weeks
The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, drugmaker Novartis said Tuesday. The drug, known as Coartem Baby or Riamet Baby in some countries, has been approved by Swiss authorities for use in babies weighing between 2 kilograms (4 pounds, 6 ounces) and 5 kilograms (11 pounds) and is formulated to be easy for them to take, Novartis said. Coartem Baby already has approval in the West African nation of Ghana and Novartis said it now expects eight African countries to grant their own approvals within 90 days. The countries – Burkina Faso, Cote d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda – also participated in the assessment of the drug. Vas Narasimhan, chief executive of Novartis, said in a news release that this first clinically proven malaria treatment for newborns and young babies ensures 'even the smallest and most vulnerable can finally receive the care they deserve.' Until now, the smallest babies have been treated for malaria, a potentially deadly disease spread by mosquitoes, with medications designed for older children. Novartis, the Swiss pharmaceutical corporation behind the newly approved drug, says this can expose newborns to the risk of overdose and toxicity. 'Most clinical trials have historically excluded babies under six months old,' Novartis spokesman Ruairidh Villar told CNN. There were 263 million cases of malaria and 597,000 deaths in 2023 – nearly all of them in Africa, according to World Health Organization data. Children under the age of 5 accounted for about three in four malaria deaths in the region. The medicine was developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV), a Switzerland-based not-for-profit organization. Novartis told CNN that it plans to 'roll out the medicine in the coming weeks on a largely not-for-profit basis.' 'Malaria is one of the world's deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated,' said Martin Fitchet, chief executive of MMV. 'The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox.'
CNN
09-07-2025
- Health
- CNN
First malaria drug for newborns and young infants expected to be approved in Africa within weeks
The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, drugmaker Novartis said Tuesday. The drug, known as Coartem Baby or Riamet Baby in some countries, has been approved by Swiss authorities for use in babies weighing between 2 kilograms (4 pounds, 6 ounces) and 5 kilograms (11 pounds) and is formulated to be easy for them to take, Novartis said. Coartem Baby already has approval in the West African nation of Ghana and Novartis said it now expects eight African countries to grant their own approvals within 90 days. The countries – Burkina Faso, Cote d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda – also participated in the assessment of the drug. Vas Narasimhan, chief executive of Novartis, said in a news release that this first clinically proven malaria treatment for newborns and young babies ensures 'even the smallest and most vulnerable can finally receive the care they deserve.' Until now, the smallest babies have been treated for malaria, a potentially deadly disease spread by mosquitoes, with medications designed for older children. Novartis, the Swiss pharmaceutical corporation behind the newly approved drug, says this can expose newborns to the risk of overdose and toxicity. 'Most clinical trials have historically excluded babies under six months old,' Novartis spokesman Ruairidh Villar told CNN. There were 263 million cases of malaria and 597,000 deaths in 2023 – nearly all of them in Africa, according to World Health Organization data. Children under the age of 5 accounted for about three in four malaria deaths in the region. The medicine was developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV), a Switzerland-based not-for-profit organization. Novartis told CNN that it plans to 'roll out the medicine in the coming weeks on a largely not-for-profit basis.' 'Malaria is one of the world's deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated,' said Martin Fitchet, chief executive of MMV. 'The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox.'
